Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study

被引:20
|
作者
Wu, Simon [1 ,2 ]
Chee, Desmond [1 ,2 ]
Ugalde, Anna [1 ,3 ]
Butow, Phyllis [4 ]
Seymour, John [2 ,5 ]
Schofield, Penelope [1 ,2 ,6 ]
机构
[1] Peter MacCallum Canc Ctr, Dept Canc Experiences Res, East Melbourne, Vic, Australia
[2] Univ Melbourne, Fac Med Dent & Hlth Sci, Parkville, Vic 3052, Australia
[3] St Vincents Hosp Melbourne, Ctr Palliat Care, Fitzroy, Vic, Australia
[4] Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia
[5] Peter MacCallum Canc Ctr, Dept Hematol, East Melbourne, Vic, Australia
[6] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia
基金
英国医学研究理事会;
关键词
Cancer; Adherence; Chronic myeloid leukemia; Qualitative; Imatinib; DOWNWARD EVALUATION; FOLLOW-UP; COMPLEMENTARY; MEDICINE; CANCER; INTERVENTIONS; ONCOLOGISTS; REGIMENS; BEHAVIOR;
D O I
10.1017/S1478951513001260
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: Consistent use of imatinib is critical for treatment success in chronic myeloid leukemia, yet perfect adherence to the prescribed clinical regimen is reported to be as low as 14%. This study aimed to understand patients' experiences of chronic myeloid leukemia with a qualitative approach, including identified facilitators and barriers to adherence, drawing on patients' and health professionals' perspectives, recording comments made by patients and health professionals involved with the same treatment team. Method: We recruited patients with chronic myeloid leukemia prescribed imatinib therapy and health professionals involved in their treatment from a specialized cancer center. Semi-structured qualitative interviews were recorded, transcribed, and manually analyzed using interpretive phenomenological analysis. Recruitment ceased upon saturation, with 16 patients and 10 health professionals (hematologists n = 4, nurses n = 3, pharmacists n = 3). Results: Twelve patients reported at least one instance of nonadherence. Reasons for unintentional nonadherence included forgetfulness related to variations of routine and doctor-patient communication issues. Reasons for intentional nonadherence included desires to reduce dose-dependent side effects and insufficient support. Patients who reported higher nonadherence rates felt complacent following periods of sustained disease control or had received conflicting advice regarding nonadherence. Health professionals had difficulty in accurately evaluating medication adherence due to a lack of reliable measures, utilizing patient self-report and manifestations of suboptimal disease control to guide assessments. Significance of Results: Adherence issues persist throughout the course of treatment. While high patient-reported nonadherence rates were recorded, health professionals were often unaware of the complex causes, compounded by an inadequacy of adherence assessment tools. Some patients reported nonadherence events because of insufficient education or lack of access to prompt medical guidance. These issues should be addressed to improve clinical practice.
引用
收藏
页码:255 / 263
页数:9
相关论文
共 50 条
  • [1] Patients' Perspectives on Adherence to Treatment in Chronic Myeloid Leukemia
    Normen, Michelle
    Surendran, V
    Ganesan, Prasanth
    Rajendranath, Rejiv
    Sagar, T. G.
    PSYCHO-ONCOLOGY, 2013, 22 : 213 - 213
  • [2] Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
    Alves, Alexandra Rodrigues
    Lima, William Gustavo
    Nagai, Michelly Martins
    Vilela Rodrigues, Joao Paulo
    Ayres, Lorena Rocha
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 52 (04) : 581 - 589
  • [3] Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia
    Jasem Al-Barrak
    Winson Y. Cheung
    Supportive Care in Cancer, 2013, 21 : 2351 - 2357
  • [4] Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia
    Al-Barrak, Jasem
    Cheung, Winson Y.
    SUPPORTIVE CARE IN CANCER, 2013, 21 (08) : 2351 - 2357
  • [5] Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study
    Sofia Jönsson
    Bob Olsson
    Jenny Söderberg
    Hans Wadenvik
    Annals of Hematology, 2012, 91 : 679 - 685
  • [6] Treatment of chronic myeloid leukemia with imatinib: IRIS study
    Saußele S.
    Nitschmann S.
    Der Internist, 2017, 58 (11): : 1220 - 1221
  • [7] Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia
    StCharles, Meaghan
    Bollu, Vamsi K.
    Hornyak, Elizabeth
    Coombs, John
    Blanchette, Christopher M.
    DeAngelo, Daniel J.
    BLOOD, 2009, 114 (22) : 870 - 870
  • [8] Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
    Waclaw, Joanna
    Sacha, Tomasz
    Stoklosa, Tomasz
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2015, 5
  • [9] Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study
    Jonsson, Sofia
    Olsson, Bob
    Soderberg, Jenny
    Wadenvik, Hans
    ANNALS OF HEMATOLOGY, 2012, 91 (05) : 679 - 685
  • [10] Erratum to: Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study
    Sofia Jönsson
    Bob Olsson
    Jenny Söderberg
    Hans Wadenvik
    Annals of Hematology, 2017, 96 : 1419 - 1419